These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 32425145)
21. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017. Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603 [TBL] [Abstract][Full Text] [Related]
22. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187 [TBL] [Abstract][Full Text] [Related]
24. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Wang D; Cummins C; Bayliss S; Sandercock J; Burls A Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692 [TBL] [Abstract][Full Text] [Related]
25. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P; Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374 [TBL] [Abstract][Full Text] [Related]
26. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
27. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML; Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087 [TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714 [TBL] [Abstract][Full Text] [Related]
29. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Cabalka AK Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269 [TBL] [Abstract][Full Text] [Related]
30. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society]. Chantepie A; Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844 [TBL] [Abstract][Full Text] [Related]
31. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL; Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032 [TBL] [Abstract][Full Text] [Related]
32. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. Gortner L Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860 [No Abstract] [Full Text] [Related]
33. Infection by the respiratory syncytial virus in infants and young children at high risk. Bonnet D; Schmaltz AA; Feltes TF Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827 [TBL] [Abstract][Full Text] [Related]
34. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil. de Souza RP; Ribeiro ALR; de Menezes SAF; Machado LFA BMC Pediatr; 2019 Aug; 19(1):299. PubMed ID: 31462289 [TBL] [Abstract][Full Text] [Related]
35. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Onuzo OC Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062 [No Abstract] [Full Text] [Related]
36. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study. Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365 [TBL] [Abstract][Full Text] [Related]